Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc.
Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc. Sanofi announced today that it has withdrawn and refiled its Premerger Notification and Report Form…
Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia
Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia Two studies, published in The Lancet and The Lancet Haematology, evaluating the efficacy and safety of fitusiran, an investigational…
Veklury®(Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations
Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from several COVID-19 clinical and real-world evidence studies being presented at the 33rd European Congress of Clinical Microbiology &…
Bristol Myers Squibb Submits Application for Abecma®, a CAR T Cell Therapy, for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least Two Prior Therapies
Bristol Myers Squibb Submits Application for Abecma®, a CAR T Cell Therapy, for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least Two Prior Therapies Bristol-Myers Squibb K.K. announced today that the company has submitted the supplemental…
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma U.S. FDA accepted Bristol Myers Squibb and 2seventy bio’s supplemental Biologics License Application and has assigned a target…
Novo Nordisk raises sales and operating profit outlook for 2023
Novo Nordisk raises sales and operating profit outlook for 2023 Novo Nordisk today announced the sales and operating profit growth at constant exchange rates (CER) for the first three months of 2023 and that the full-year sales and operating profit…
Aspect Biosystems and Novo Nordisk enter partnership to develop bioprinted tissue therapeutics for diabetes and obesity
Aspect Biosystems and Novo Nordisk enter partnership to develop bioprinted tissue therapeutics for diabetes and obesity Aspect Biosystems and Novo Nordisk A/S today announced a collaboration, development, and licence agreement to develop bioprinted tissue therapeutics designed to replace, repair, or…
Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation
Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the European Commission (EC) granted marketing authorization in the European Union (EU) for a citrate-free high…
FDA approves Roche’s Policy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma
FDA approves Roche’s Policy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Polivy® (polatuzumab…
Roche’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
Roche’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new data from the Phase III IMbrave050 study…
Roche data highlights the strength of the ophthalmology portfolio and commitment to advancing eye care at ARVO 2023
Roche data highlights the strength of the ophthalmology portfolio and commitment to advancing eye care at ARVO 2023 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data for its approved and investigational medicines will be highlighted in 30…
AMGEN WINS PATENT APPEAL ON OTEZLA® (APREMILAST)
AMGEN WINS PATENT APPEAL ON OTEZLA® (APREMILAST) Amgen (NASDAQ:AMGN) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the District of New Jersey in a patent infringement lawsuit against Sandoz Inc. (“Sandoz”) and Zydus Pharmaceuticals…